Monogram获FDA批准用于膝关节手术系统
Monogram mBōs™ TKA系统旨在提高膝关节置换手术的安全性、效率和精确度。该系统有望扩展应用于各种骨科手术，在市场渗透率仍较低且整合度不断提高的环境下，为未来增长提供平台。虽然 InvestingPro 分析显示公司拥有强健的资产负债表，现金多于债务，流动比率达10.7，但公司面临显著的现金消耗挑战，过去十二个月EBITDA为负1487万美元。
Monogram Orthopaedics price target raised to $5.40 from $4 at Roth MKM
Roth MKM raised the firm’s price target on Monogram Orthopaedics (MGRM) to $5.40 from $4 and keeps a Buy rating on the shares. The company’s ...
Monogram Orthopaedics第四季度财报：战略性增长显著提升
Monogram Orthopaedics Inc. (MGRM) 在2024年第四季度以1570万美元的现金余额收官，这得益于一轮成功募集的1300万美元资金。该公司正在开发一套创新的自动化机器人膝关节置换手术系统，月度现金消耗已降至110万美元。尽管财务状况向好，Monogram股票盘后交易表现温和，上涨0.43%至2.33美元。
MassDevice1 天
FDA clears robotic knee surgery system from Monogram Technologies
Monogram Technologies (Nasdaq:MGRM) announced today that it received FDA 510(k) clearance for its mBôs total knee ...
Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System
Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act).
Monogram Orthopaedics announces 510(k) clearance for mBos TKA System
Monogram Technologies announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Monogram mBos TKA System. This ...
腾讯网6 天
路易威登发布Color Blossom珠宝系列新作
深植路易威登品牌历史的Color ...